ERBB2 and breast cancer: Indeed, analysis of the NeoALTTO trial shows a tendency towards a lower pCR rate for the overweight/obesity patients compared to the under/normal weight patients in HR + /HER2+ (OR = 0.56, P = 0.054), but not in HR-/HER2+ (OR = 1.31, P = 0.324) breast cancer patients11.